Gyre Therapeutics, Inc.: 10-Q filed 2025-11-07
What Gyre Therapeutics, Inc. reported in its quarterly report filed 2025-11-07 (fiscal Q3 2025): 52 published measures, 145 facts as tagged in accession 0001193125-25-272383.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-07
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001193125-25-272383 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Gyre Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 159,384,000 | USD | |
| At 2024-12-31 | 125,406,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 21,969,000 | USD | |
| At 2024-12-31 | 27,004,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 101,920,000 | USD | |
| At 2024-12-31 | 63,319,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 40,402,000 | USD | |
| At 2024-12-31 | 11,813,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 5,936,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 11,200,000 | USD | 273 |
| 2025-04-01 to 2025-06-30 | 1,576,000 | USD | 91 |
| 2025-01-01 to 2025-03-31 | 3,734,000 | USD | 90 |
| 2024-07-01 to 2024-09-30 | 2,856,000 | USD | 92 |
| 2024-04-01 to 2024-06-30 | 4,538,000 | USD | 91 |
| 2024-01-01 to 2024-03-31 | 9,935,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 6,635,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -883,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,046,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 2,380,000 | USD | 274 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 30,564,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 79,393,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 25,488,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 77,885,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 24,060,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,138,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -2,322,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -17,880,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -66,703,000 | USD | |
| At 2024-12-31 | -73,453,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 90,850,040 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 88,707,709 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 85,643,646 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 84,807,041 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 103,971,546 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 102,813,522 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 102,640,373 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 102,505,585 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.04 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | 0.08 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | 0.01 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | 0.14 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.03 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | 0.04 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | 0.01 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | 0.05 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 1,693,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 3,256,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 1,074,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 5,117,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 23,608,000 | USD | |
| At 2024-12-31 | 23,880,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 2,560,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 264,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 6,925,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 11,369,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 4,233,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 15,498,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 98,576,000 | USD | |
| At 2024-12-31 | 64,786,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 15,913,000 | USD | |
| At 2024-12-31 | 19,516,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 556,000 | USD | |
| At 2024-12-31 | 108,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 4,847,000 | USD | |
| At 2024-12-31 | 273,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 25,877,000 | USD | |
| At 2024-12-31 | 19,589,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 22,011,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 64,351,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 20,297,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 59,680,000 | USD | 274 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 28,936,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 75,720,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 24,530,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 75,178,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,363,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 8,883,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,775,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 8,312,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 90,890,381 | shares | |
| At 2024-12-31 | 86,307,544 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 167,134,000 | USD | |
| At 2024-12-31 | 136,185,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -1,700,000 | USD | |
| At 2024-12-31 | -2,597,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 137,415,000 | USD | |
| At 2025-06-30 | 129,443,000 | USD | |
| At 2025-03-31 | 104,302,000 | USD | |
| At 2024-12-31 | 98,402,000 | USD | |
| At 2024-09-30 | 98,474,000 | USD | |
| At 2024-06-30 | 93,346,000 | USD | |
| At 2024-03-31 | 88,771,000 | USD | |
| At 2023-12-31 | 13,949,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,300,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,165,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 30,542,000 | USD | |
| At 2024-12-31 | 29,479,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 6,934,000 | USD | |
| At 2024-12-31 | 5,599,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 5,322,000 | USD | |
| At 2024-12-31 | 6,280,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,427,000 | USD | |
| At 2024-12-31 | 7,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 2,873,000 | USD | |
| At 2024-12-31 | 2,625,000 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 58,000 | USD | |
| At 2024-12-31 | 61,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 7,629,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 14,502,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,930,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 22,446,000 | USD | 274 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 11,246,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 17,329,000 | USD | 274 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 4,198,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 7,648,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,188,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 12,882,000 | USD | 274 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 3,610,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 6,750,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 1,124,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 12,184,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 4,319,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 14,103,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,823,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 10,645,000 | USD | 274 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,825,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,088,000 | USD | 274 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 170,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 404,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 10,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 26,000 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 727,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 689,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -75,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -25,000 | USD | 274 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 4,493,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 7,757,000 | USD | 274 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 564,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 631,000 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 5,981,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 4,111,000 | USD | 274 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 2,423,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 2,021,000 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 446,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -55,000 | USD | 274 |
Inspect the source
- Entity
- Gyre Therapeutics, Inc. / CIK 0001124105
- Captured
- 2026-09-20T07:40:18.545Z
- SEC response SHA-256
76d6d577c67b9fd5657091e03be7ffe01a1cac0d3d9b5ad24843327a50d791e0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001124105.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))